4'-O-SULFONYL-ANTHRACYCLINE DERIVATIVES

Abstract: Compounds which are anthracycline glycosides of general formula (1) or (2), wherein R1 is hydrogen or a methoxy group; one of R2 and R3 is hydrogen and the other is a sulfonyl residue R4SO2O- in which R4 is a linear or branched C1-C8 alkyl, or an aryl which is unsubstituted or substituted with at least one linear or branched C1-C6 alkyl or a C1-C6 alkoxy group, a halogen atom, an amino or a nitro group; or a pharmaceutically acceptable salt thereof are active as antitumor agents. A process for the preparation thereof and pharmaceutical compositions containing such a compound are also disclosed.

Description: 4 ' -O-SϋLFOr-ryL-ΑNTmiACYCLINE DERIVATIVES The invention relates to new anthracycline glycosides, to a process for their preparation and to pharmaceutical compositions containing them. A new class of anthracycline glycoside antibiotics in which the 4 , -hydroxy group of the sugar residue is substituted with a sulfonate has now been found. The present invention therefore provides a compound which is an anthracycline glycoside of formula 1 or 2 wherein R-. is hydrogen or a methoxy group; one of R 2 and R 3 is hydrogen and the other is a sulfonyl residue R J SO- J O- in which R 4 is a linear or branched Cj-Cg alkyl, or an aryl which is unsubstituted or substituted with at least one linear or branched C,-C 6 alkyl or C,-C 6 alkoxy group, a halogen atom, an a ino or a nitro group; or a pharmaceutically acceptable salt thereof. In particular R, may be a linear or branched alkyl group containing from 1 to 6 carbon atoms, for example 1 to 4 carbon atoms; R 4 may in particular be methyl, ethyl, n- propyl, iεopropyl. Alternatively, may be an aryl group such as a phenyl group, unsubstituted or substituted by 1 to 3 substituents each of which may independently be a linear or branched alkyl or alkoxy group of from 1 to 3 carbon atoms, a halogen atom or a nitro group. Halogen in the present text means fluorine, chlorine, bromine or iodine, preferably fluorine or chlorine, more preferably chlorine. Particularly preferred salts of the compounds of the present invention are pharmaceutically acceptable addition salts such as hydrochlorides. Particularly preferred compounds of formula 1 include: (la) 4 / -0-methansulfonyldaunorubicin R 3 =H) (lb) 4-demethoxy-4'-0-methansulfonyldaunorubicin (R,=R 3 =H, R 2 =CH 3 S0 2 0) (lc) 4 , -epi-4 , -0-methansulfonyldaunorubicin (Rι=0CH 3 , R 2 =H, R 3 =CH 3 S0 2 0) Particularly preferred compounds of formula 2 include: (2a) 4'-0-methansulfonyldoxorubicin R 2 =CH 3 S0 2 0) ( 2b) 4-demethoxy-4 ' -0-methansulfonyldoxorubicin (R,=R 3 =H , R 2 =CH 3 S0 2 0) ( lc) 4 , -epi-4 ' -0-methansulfonyldoxorubicin (R,=OCH 3 , R 2 =H, R 3 =CH 3 S0 2 0) Accordingly, the present invention provides a process for the preparation of a compound which is an anthracycline glycoside of formula 1 or 2 as above defined or a pharmaceutically acceptable salt thereof, which process comprises: (a) reacting an anthracycline of general formula 3 wherein, R-, has the same meaning as above defined, R 5 represents an amino protecting group, one of $ and R 7 is hydrogen and the other is hydroxy, with a substituted sulfonyl halogen derivative of formula 4 R 4 SO 2 -X 4 wherein R, has the same meaning as defined above and X is halogen, preferably chlorine, in the presence of a weak organic base; and (b) isolating the N-protected derivative of formula 5 wherein R,, R 2 , R 3 and R 5 are as above defined and preferably purifying said derivative e.g. by column chromatography; (c) deblocking the N-protected amino group of said derivative 5 in the presence. of a base preferably at from 0°C to 5°C and for 4 to 8 hours; and if desired, converting the compound of formula 1 thus obtained into a pharmaceutically acceptable salt thereof; or (d) converting a compound of formula 1 into the corresponding derivative of formula 2 by hydroxylation at the C-14 position e.g. following the procedure described in US Patent No: 3,803,124 and, if desired, converting the compound of formula 2 thus obtained into a pharmaceutically acceptable salt thereof. It should be noted that use of weak organic base in step (a) avoids εulfonylation at phenolic hydroxyl. As examples of starting anthracyclines of general formula 3 there may be given: N-trifluoroacetyldaunorubicin (3a: R,=OCH 3 , R 5 =NHCOCF 3 , R<*=0H, R 7 =H) , 4-demethoxy-N- trifluoroacetyldaunourubicin (3b: R^R^H, R 5 =NHCOCF 3 , R 5 =NHCOCF 3 , R 6 =H, R 7 =0H) . Said derivatives may be prepared as described by F. Arcamone in "DOXORUBICIN" Medicinal Chemistry, Vol. 17, Academic Press INC (London) 1981. Other compounds of formula 3 may be prepared by analogous methods. The O-sulfonylation of compound 3 is typically carried out using an excess, e.g. from 1.2 to 20 equivalents preferably 1.2 to 5 equivalents, of halo sulfonyl derivative . The weak organic base present in step (a) may be provided by carrying out the reaction in an appropriate medium. For example, depending on the reactivity of the sulfonylating agent, the reaction may be carried out in anhydrous pyridine and can usually be completed from 15 to 60 hours, at a temperature from 0°C to room temperature, preferably at about 4°C. Alternatively, the reaction may be carried out in an organic solvent, such as dry methylene chloride, in the presence of an organic base e.g. pyridine or collidine. The reaction can usually be completed from 15 to 60 hours, at a temperature from 0°C to room temperature, preferably at about 4°C. The reaction product is isolated, as N-trifluoroacetate derivative (5) from the reaction mixture e.g. by solvent extraction and preferably purified e.g. by column chromatography ' . In order to deblock the N-protected group, the N-trifluoroacetate- 4 , -0-sulfonyl derivative is subjected to basic conditions e.g. contacting with aqueous 0.1 to 0.5N sodium hydroxide, at a temperature from 0°C to 5°C, for a time from 4 to 8 hours. The product thus obtained may be extracted from the reaction mixture e.g. with methylene chloride, the organic solvent concentrated to small volume, and the desired product isolated as its hydrochloride by treatment with ethanolic hydrogen chloride. In order to prepare sulfonated anthracycline glycosides of formula 2, compounds 1 are hydroxylated at C-14 for example as described in US Patent No: 3,803,124. The products may be obtained as their hydrochloride by treatment with methanolic hydrogen chloride. As a further aspect, the invention provides pharmaceutical compositions comprising an anthracycline glycoside of formula 1 or 2 or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable diluent or carrier. Conventional carriers and diluents may be used. The compositions may be formulated and administered in a conventional manner. Suitable routes of administration include paren-eral administration. For parenteral administration a liquid formulation may be prepared using the active compound and a sterile diluent or carrier which may either dissolve the active compound or provide a suspension for it. The parenteral formulation may be prepared in the form of a sterile solid for reconstitution prior to administration with a suitable vehicle such as physiological saline, sterile water or other sterile vehicle. The compounds of the invention are useful in methods of treatment of the human and animal body by therapy. They are useful as anti-tumor agents in particular in the treatment of leukaemia or colon adenocarcinoma. A therapeutically effective amount is administered to a patient having a tumor to ameliorate or improve the condition of the patient. An amount sufficient to inhibit the growth of the tumor may be administered. The dosage to be given can be ascertained using known dosage ranges for doxorubicin and daunorubicin modified by reference to the activity shown by the present compounds in in vitro and in vivo anti-tumor tests. Suitable dosages are generally in the range of 1 to 200 mg/m 2 body surface preferably from 1 to 100 mg/m 2 depending on the nature and severity of the disease being treated and on the general condition of the patient. The following examples illustrate the invention. EXAMPLE 1: Preparation of 4'-Q-methansulfonyldaunorubicin (la; R,=OCH,, R- CH*,S0-.0. R*,=H) N-trifluoroacetyldaunorubicin (3a: 5g, 8.2 mmol) was dissolved in dry pyridine (30 ml) and added to methanesulfonyl chloride (0.9 ml, 11.5 mmol) at 0°C. The reaction mixture was stirred for 1.5 hours, and subsequently poured onto ice. The precipitate was collected, washed with water and dried to give 4'-0- methansulfonyl-N-trifluoroacetyldaunorubicin (5a, 5.6 g) . TLC plate on Kieselgel F258 (Merck) , with an eluting system of methylene chloride/methanol (20:1 by volume) Rf=0.57. Compound 5a (4g) was added to aqueous 0.3N sodium hydroxide (200 ml) and stirred at 10-15°C for 6 hours. The reaction mixture was then brought to pH 3 with IN hydrochloric acid and extracted with methylene chloride. The aqueous solution was brought to pH 7.5 and extracted with methylene chloride (3x100 ml) . The organic phase was washed with water, dried over anhydrous sodium sulfate, concentrated under reduced pressure and treated with a solution of methanolic anhydrous hydrogen chloride to give, after precipitation with ethyl ether, the title compound la (2.6 g) . TLC plate on Kieselgel F258 (Merck), eluting system methylene chloride/methanol (10:1 by volume) Rf=0.35. FD-MS: m/z 605 (M+) E AMPLE 2 Preparation of 4-demethoxy-4 f -O-methansulfonyldaunorubicin flbt R,=R,=H. R 7 =CH,SO,Q) The title compound lb was prepared starting from 4- demethoxy-N-trifluoroacetyldaunorubicin (3b: 5.7 g, 10 mmol) following the same procedure described in Example 1. Yield of lb: 3 g. TLC plate on Kieselgel F258 (Merck) , eluting system methylene chloride/methanol (10:1 by volume) Rf=0.5. EXAMPLE 3 Preparation of 4 -Q-methansulfonyldoxorubicin 4'-0-methansufonyldaunorubicin hydrochloride (la: 0.6 g, 1 mmol) prepared as described in Example 1 was converted into the title compound 2a as described in US Patent No: 3,803,124 (yield 0.4 g) . TLC plate on Kieselgel F258 (Merck) , eluting system methylene chloride/methanol (10:1 by volume) Rf=0.21; m.p. 157-158°C; FD-MS: m/z 621 (M+). Biological activity 4'-0-methansufonyl derivatives lb and 2a were tested in vitro on two human cell lines, LoVo (colon adenocarcinoma) and LoVo/DX (colon adenocarcinoma resistant to doxorubicin) in comparison with doxorubicin. The cytotoxic activity is reported as IC50, the concentration inhibiting 50% of colony formation, calculated on concentration response curves. Resistance index R.I. is the ratio between the IC50 on resistant cells and the IC50 on sensitive cells. Both compounds were found more cytotoxic than doxorubicin (Table I) . Compounds lb and 2a were also evaluated in vivo against P388 murine leukaemia resistant to doxorubicin (10 s cell/mouse transplanted i.v. in BD2F1 mice) in comparison with doxorubicin (Table II) . The introduction of a sulfonyl residue at position C-4' of anthracycline produces a new class of anthracyclines endowed with activity against doxorubicin- resistant tumors. Table I: in vivo cytotoxic activity (IC50) of compound lb and 2a on LoVo and LoVo/DX cells in comparison with doxorubicin. 10 Colony assay: 4 h treatment (1) IC50 = concentration inhibiting 50% colony formation; 0) R.I. = Resistance Index = (IC50 LoVo/DX)/(IC50 Lo V o ) . --5 Table II: Antitumor activity of lb and 2a on P388/DX leukaemia in comparison with doxorubicin. 0 The compounds were injected i.v. one day after tumor transplantation. 0) Optimal Dose 5 C) Median survival time of treated mice/Median survival time of controls x 100.

Claims: - 11 - CLAIMS 1. A compound which is an anthracycline glycoside of general formula 1 or 2: wherein R-. is hydrogen or a methoxy group; one of R 2 and R 3 is hydrogen and the other is a sulfonyl residue RήSOjO- in which t is a linear or branched Cj-C 8 alkyl, or an aryl group which is unsubstituted or substituted with at least one linear or branched C,-C 6 alkyl or C,-C 6 alkoxy group, a halogen atom, an amino or a nitro group; or a pharmaceutically acceptable salt thereof. 2. A compound according to claim l, wherein R» is methyl, ethyl, n-propyl or isopropyl. 3. A compound according to claim 1, wherein R, is an aryl group which is unsubstituted or substituted by 1 to 3 substituents each of which may independently be a linear or branched alkyl or an alkoxy group of from 1 to 3 carbon atoms. 4. A compound according to claim 1, which is: (la) 4 , -0-methansulfonyldaunorubicin (R-^OCH-,, R 2 =CH 3 S0 2 0 , R 3 =H) (lb) 4-demethoxy-4'-0-methansulfonyldaunorubicin (Rι=R 3 =H, R 2 =CH 3 S0 2 0) (lc) 4'-epi-4'-0-methansulfonyldaunorubicin (Rι=OCH 3 R 2 =H, R 3 =CH 3 S0 2 0) (2a) 4'-0-methansulfonyldoxorubicin (R,=OCH 3 , R 3 =H, R 2 =CH 3 S0 2 0) (2b) 4-demethoxy-4'-0-methansulfonyldoxorubicin (R,=R 3 =H, R 2 =CH 3 S0 2 0) (2c) 4 f -epi-4 , -0-methansulfonyldoxorubicin (R j =OCH 3 , R 2 =H, R 3 =CH 3 S0 2 0) , or a pharmaceutically acceptable salt thereof. 5. A compound according to any one of claims 1 to 3, which is in the form of a hydrochloride salt. 6. A process for the preparation of a compound as defined in any one of claims 1 to 5, which process comprises: (a) reacting an anthracycline of general formula 3 wherein R, is as defined in claim 1, R 5 represents an amino protecting group, one of Rj and R 7 is hydrogen and the other is hydroxy, with a substituted sulfonyl halogen derivative of formula 4 R 4 S0 2 -X 4 wherein R« is as defined in claim 1 and X is halogen, in the presence of a weak organic base; (b) isolating the N-protected derivative of formula 5_ wherein R R 2 , R 3 and R 5 are as defined in claim 1; (c) deblocking the N-protected amino group of said derivative 5 in the presence of a base; and if desired, converting the compound of formula 1 thus obtained into a pharmaceutically acceptable salt thereof; or (d) converting a compound of formula 1 by hydroxylation into the corresponding derivative of formula 2 and, if desired, converting the compound of formula 2 thus obtained into a pharmaceutically acceptable salt thereof. 7. A process according to claim 6, wherein the halogen is chlorine. 8. A process according to claim 6 or 7, wherein the organic base used in step (a) is selected from the group of pyridine and collidine. 9. A process according to claim 6, 7 or 8, wherein the base used in step (c) is sodium hydroxide. 10. A process according to any one of claims 6 to 9, wherein step (a) is carried out in an organic solvent at from 0°C to room temperature for 15 to 60 hours, the purification in step (b) is carried out using column chromatography and step (c) is carried out at from 0°C to 5°C for 4 to 8 hours. 11. A process according to claim 10, wherein the organic solvent is pyridine or methylene chloride. 12. A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and, as an active principle, a compound as defined in any one of claims 1 to 5. 13. An anthracycline glycoside of formula' 1 or 2 or a pharmaceutically acceptable salt thereof, as defined in claim 1, for use in a method of treatment of the human or animal body by therapy. 14. An anthracycline glycoside or a pharmaceutically acceptable salt thereof as defined in claim 1, for use as an anti-tumor agent.

Inventors: BARGIOTTI ALBERTO, CARUSO MICHELE, GRANDI MARIA, RIPAMONTI MARINA, SUARATO ANTONINO, BARGIOTTI, ALBERTO, CARUSO, MICHELE, GRANDI, MARIA, RIPAMONTI, MARINA, SUARATO, ANTONINO
Applicants: PHARMACIA SPA, PHARMACIA S.P.A.
Application year: 1994
Main classification: C07H15
IPC codes: A61K31, A61P35, C07H15